3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Myeloid
2
Lymphoid
2
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
76
Anemia, Refractory, with Excess of Blasts
72
Myelodysplastic Syndromes
69
Leukemia
54
Precursor Cell Lymphoblastic Leukemia-Lymphoma
51
Anemia
50
Leukemia, Lymphocytic, Chronic, B-Cell
44
Leukemia, Myelomonocytic, Chronic
42
Lymphoma, Non-Hodgkin
41
Multiple Myeloma
38
Hodgkin Disease
36
Myeloproliferative Disorders
34
Primary Myelofibrosis
33
Thrombocytopenia
32
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
32
Lymphoma
31
Neoplasms
29
Anemia, Aplastic
29
Congenital Abnormalities
27
Anemia, Refractory
25
Lymphoma, Follicular
23
Lymphoma, Mantle-Cell
21
Lymphoma, B-Cell, Marginal Zone
18
Burkitt Lymphoma
18
Lymphoma, Large B-Cell, Diffuse
17
Leukemia, Myeloid, Chronic-Phase
17
Venous Thromboembolism
16
Lymphoma, Large-Cell, Immunoblastic
16
Leukemia, Myeloid, Accelerated Phase
16
Waldenstrom Macroglobulinemia
14
Interventions
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hemorrhagic Disorders
×
Classical hematology
×
Clear all
NCT02055781
2021-11-18
PAC326
CTI BioPharma
Phase 3
Terminated
311 enrolled
12 charts